A Return to Profit
Third-quarter results show a clear recovery for Moderna after years of declining revenue. The key figures include:
- Revenue rose 29% to $1.3 billion, including $780 million in the United States and $533 million in international markets.
- Net profit reached $162 million, a $362 million improvement from the year-earlier loss.
- Research and development expenses fell 27% to $583 million.
- The 2026 revenue growth forecast was raised to 15% to 25%; year-end cash is expected at $8.1 billion to $8.3 billion.
We delivered 29% revenue growth in the third quarter.
Momentum From International Markets
According to Moderna, the revenue increase was driven mainly by higher COVID-19 vaccine sales in international markets, supported by deliveries under long-term strategic agreements with the governments of the United Kingdom, Canada and Australia. In September, the company signed a five-year agreement with a manufacturer in Mexico, expanding its recurring revenue.

















